DrugBiological
Hyaluronidase (human recombinant) clinical trials
Also written rHuPH20, Hylenex and Chemophase.
Keep track of what changes. Save the hyaluronidase (human recombinant) studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- rHuPH20
- 19
Studies by the year they started
77 studies that test it; most in 2024 (8)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 6 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 2 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 65 · Other 12
argenx (24) · Halozyme Therapeutics (18) · ViiV Healthcare (3) · Baxalta now part of Shire (3) · Baxter Healthcare Corporation (3) · Bristol-Myers Squibb (2) · Alexion Pharmaceuticals, Inc. (2) · Shire (2)
Often tested with
Tested in the same studies.
Efgartigimod alfa (23) · Daratumumab (5) · Insulin Lispro (4) · Insulin, Regular, Human (3) · Lenalidomide (2) · Cabotegravir (2) · C1 esterase inhibitor (human) (2) · Insulin, Regular (2)
Related medicines
As reviewed, each with the page that says it.
- One of Hyaluronoglucosaminidase source
Studies
Open first, then newest update. How each study uses hyaluronidase (human recombinant) is read from its arms, and is right about nine times in ten.
Testing it · 77
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyEnrolling by invitationPhase 3argenxNCT05979441Written as Efgartigimod PH20 SC
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' DiseaseRecruitingPhase 3argenxNCT07570316Written as Efgartigimod PH20 SC
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.RecruitingPhase 3argenxNCT07596849Written as efgartigimod PH20 SC
- A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisRecruitingPhase 2/3argenxNCT06392386Written as Efgartigimod PH20 SC
- A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)Not yet recruitingPhase 2argenxNCT07760818Written as efgartigimod PH20 SC
- A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of CareNot yet recruitingPhase 1GlaxoSmithKlineNCT07742527Written as Recombinant Human Hyaluronidase PH20 (rHuPH20)
- A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy SubjectsNot yet recruitingPhase 1Shanghai Henlius BiotechNCT07484893Written as recombinant human hyaluronidase
- A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)RecruitingPhase 4argenxNCT06909214Written as Efgartigimod PH20 SC
- A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsRecruitingPhase 1ViiV HealthcareNCT05418868Written as rHuPH20
- Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm StudyRecruitingNot applicableYongyong MANCT06455748Written as Daratumumab/daratumumab and hyaluronidase-fihj
- A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20Active, not recruitingPhase 1PfizerNCT07792941Written as tilrekimig and rHuPH20
- A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaActive, not recruitingPhase 3argenxNCT04812925Written as efgartigimod PH20 SC
- A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic SclerosisActive, not recruitingPhase 2argenxNCT06655155Written as Efgartigimod PH20 SC
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationActive, not recruitingPhase 3SWOG Cancer Research NetworkNCT04071457Written as Daratumumab/rHuPH20
- A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsActive, not recruitingPhase 2Bristol-Myers SquibbNCT06101134Written as relatlimab+nivolumab+rHuPH20
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03281369Written as PEGylated recombinant human hyaluronidase (PEGPH20)
- A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)Active, not recruitingPhase 2ViiV HealthcareNCT05996471Written as rHuPH20
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisActive, not recruitingPhase 3argenxNCT06558279Written as Efgartigimod PH20 SC
- A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromeActive, not recruitingPhase 3argenxNCT06684847Written as Efgartigimod PH20 SC
- A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SCCompletedPhase 4argenxNCT06637072Written as Efgartigimod PH20 SC
See all 77 studies that test hyaluronidase (human recombinant) →
Given in every arm · 17 — hyaluronidase (human recombinant) is usual care beside what is tested
- A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care TherapyRecruitingPhase 1AstraZenecaNCT07161414Written as Recombinant Human Hyaluronidase (rHu)
- First Time in Human Study of Long Acting VH4524184 FormulationsRecruitingPhase 1ViiV HealthcareNCT06310551Written as rHuPH20
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaActive, not recruitingPhase 3Bristol-Myers SquibbNCT05625399Written as rHuPH20
- Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult ParticipantsCompletedPhase 1ViiV HealthcareNCT04484337Written as Recombinant human hyaluronidase PH20 (rHuPH20)
- dMAbs for Prevention of COVID-19CompletedPhase 1Pablo TebasNCT05293249Written as Hylenex
- A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedPhase 3Hoffmann-La RocheNCT03735121Written as rHuPH20
- An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have SpreadTerminatedPhase 1/2Bristol-Myers SquibbNCT03446040Written as rHuPH20
- A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple SclerosisCompletedPhase 1Hoffmann-La RocheNCT03972306Written as rHuPH20
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT03320707Written as rHuPH20
- A Phase 1, Bioavailability Study of Relatlimab in Combination With NivolumabCompletedPhase 1Bristol-Myers SquibbNCT04112498Written as rHuPH20
- An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With NivolumabCompletedPhase 1/2Bristol-Myers SquibbNCT02754141Written as rHuPH20
- A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesTerminatedPhase 1Bristol-Myers SquibbNCT04311710Written as ENHANZE (rHuPH20)
- Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20CompletedPhase 1Halozyme TherapeuticsNCT00705536Written as Recombinant human hyaluronidase PH20 (rHuPH20)
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes MellitusCompletedPhase 2Halozyme TherapeuticsNCT01194245Written as recombinant human hyaluronidase PH20
- Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20CompletedPhase 1Halozyme TherapeuticsNCT00803972Written as rHuPH20
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes MellitusCompletedPhase 2Halozyme TherapeuticsNCT01194258Written as Recombinant human hyaluronidase PH20
- Efficacy of Hylenex in the Treatment of Pain Among Hospice PatientsCompletedNot applicableHPC Healthcare, Inc.NCT00547664Written as Hylenex recombinant , morphine, saline
Codes
What other systems call hyaluronidase (human recombinant) · ClinicalTrials.gg INT015395
- UNII (FDA) 743QUY4VD8HYALURONIDASE (HUMAN RECOMBINANT)Confirmed FDA, Wikidata
- RxNorm 1300478One source FDA
- Wikidata Q904015hyaluronidaseConfirmed FDA, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 743QUY4VD8 | HYALURONIDASE (HUMAN RECOMBINANT) | Confirmed FDA, Wikidata |
| RxNorm | 1300478 | — | One source FDA |
| Wikidata | Q904015 | hyaluronidase | Confirmed FDA, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.